Enliven Therapeutics Inc
NASDAQ:ELVN
Intrinsic Value
Enliven Therapeutics, Inc. operates as a a clinical stage precision oncology company. [ Read More ]
The intrinsic value of one ELVN stock under the Base Case scenario is 5.42 USD. Compared to the current market price of 23.43 USD, Enliven Therapeutics Inc is Overvalued by 77%.
Valuation Backtest
Enliven Therapeutics Inc
Run backtest to discover the historical profit from buying and selling ELVN stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Enliven Therapeutics Inc
Current Assets | 266.2m |
Cash & Short-Term Investments | 253.1m |
Other Current Assets | 13m |
Non-Current Assets | 5.7m |
PP&E | 1.1m |
Other Non-Current Assets | 4.7m |
Current Liabilities | 25.9m |
Accounts Payable | 532k |
Accrued Liabilities | 15.4m |
Other Current Liabilities | 10m |
Non-Current Liabilities | 67k |
Other Non-Current Liabilities | 67k |
Earnings Waterfall
Enliven Therapeutics Inc
Revenue
|
0
USD
|
Operating Expenses
|
-83.5m
USD
|
Operating Income
|
-83.5m
USD
|
Other Expenses
|
11.9m
USD
|
Net Income
|
-71.6m
USD
|
Free Cash Flow Analysis
Enliven Therapeutics Inc
ELVN Profitability Score
Profitability Due Diligence
Enliven Therapeutics Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.
Score
Enliven Therapeutics Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.
ELVN Solvency Score
Solvency Due Diligence
Enliven Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Enliven Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ELVN Price Targets Summary
Enliven Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for ELVN is 35.02 USD with a low forecast of 32.32 USD and a high forecast of 38.85 USD.
Ownership
ELVN Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
ELVN Price
Enliven Therapeutics Inc
Average Annual Return | 11.14% |
Standard Deviation of Annual Returns | 87.56% |
Max Drawdown | -98% |
Market Capitalization | 1.1B USD |
Shares Outstanding | 46 704 800 |
Percentage of Shares Shorted | 24.87% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Enliven Therapeutics, Inc. operates as a a clinical stage precision oncology company. The company is headquartered in Boulder, Colorado and currently employs 6 full-time employees. The company went IPO on 2020-03-12. The firm focuses on addressing existing and emerging unmet needs with a precision oncology approach. The firm is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, as well as pursuing several additional research stage opportunities. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia (CML). Its second product candidate, ELVN-002, is a potent, selective and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against various HER2 mutations, including Exon 20 insertion mutations (E20IMs) in non-small cell lung cancer (NSCLC).
Contact
IPO
Employees
Officers
The intrinsic value of one ELVN stock under the Base Case scenario is 5.42 USD.
Compared to the current market price of 23.43 USD, Enliven Therapeutics Inc is Overvalued by 77%.